• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Klapstein Julie D was granted 9,736 shares (SEC Form 4)

    6/9/25 4:15:06 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care
    Get the next $OMDA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Klapstein Julie D

    (Last) (First) (Middle)
    C/O OMADA HEALTH, INC.
    500 SANSOME STREET, SUITE 200

    (Street)
    SAN FRANCISCO CA 94111

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Omada Health, Inc. [ OMDA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/05/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/05/2025 A 9,736(1) A $0 9,736 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs will fully vest on the first anniversary of June 5, 2025.
    /s/ Nathan Salha, as Attorney-in-Fact for Julie D. Klapstein 06/09/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $OMDA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OMDA

    DatePrice TargetRatingAnalyst
    7/1/2025$21.00Outperform
    Evercore ISI
    7/1/2025$25.00Overweight
    Morgan Stanley
    7/1/2025$19.00Overweight
    Analyst
    7/1/2025$23.00Buy
    Needham
    7/1/2025$21.00Overweight
    Barclays
    7/1/2025$29.00Buy
    Goldman
    7/1/2025$27.00Buy
    Canaccord Genuity
    More analyst ratings

    $OMDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on Omada Health with a new price target

    Evercore ISI initiated coverage of Omada Health with a rating of Outperform and set a new price target of $21.00

    7/1/25 8:41:36 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Morgan Stanley initiated coverage on Omada Health with a new price target

    Morgan Stanley initiated coverage of Omada Health with a rating of Overweight and set a new price target of $25.00

    7/1/25 8:21:32 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Analyst initiated coverage on Omada Health with a new price target

    Analyst initiated coverage of Omada Health with a rating of Overweight and set a new price target of $19.00

    7/1/25 8:21:32 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    $OMDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Omada Health Reports Second Quarter 2025 Results

    Revenue of $61 million, up 49%52% Member Growth and Significant Progress Toward Profitability SAN FRANCISCO, Aug. 07, 2025 (GLOBE NEWSWIRE) --  Omada Health, Inc. (NASDAQ:OMDA), the virtual between-visit healthcare provider, today reported financial results for the second quarter ended June 30, 2025. 2025 Second Quarter Highlights Total Members of 752,000, up 52% compared to the second quarter of 2024Revenue of $61 million, up 49% compared to the second quarter of 2024GLP-1 Companion Success, with strong growth in members being supported by Omada's GLP-1 companion programs - now available through two of the largest pharmacy benefit managers in the United StatesOmada Horizon Day: In M

    8/7/25 4:05:00 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Omada Health to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

    SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2025 results on Thursday, August 7, 2025, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details Those participating in the conference call can pre-register using the following link: https://register-conf.media-server.com/register/BIce129368a015484a8f39659a48a1631e. A live audio webcast of the call will also be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same l

    7/17/25 4:30:00 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Omada Health's Enhanced GLP-1 Care Track Demonstrates Increased Medication Persistence and Weight Loss Outcomes at 12 and 24 Weeks

    SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada's GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss.2 Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings.1 Despite a growing body of evidence supporting vast clinical benefits of GLP-1s,3 while results vary widely, one study showed that one-third of people stopped taking their GLP-1 in

    6/17/25 9:00:00 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    $OMDA
    Leadership Updates

    Live Leadership Updates

    View All

    Omada Health's Enhanced GLP-1 Care Track Demonstrates Increased Medication Persistence and Weight Loss Outcomes at 12 and 24 Weeks

    SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada's GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss.2 Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings.1 Despite a growing body of evidence supporting vast clinical benefits of GLP-1s,3 while results vary widely, one study showed that one-third of people stopped taking their GLP-1 in

    6/17/25 9:00:00 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    $OMDA
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Omada Health Inc.

    SCHEDULE 13G - Omada Health, Inc. (0001611115) (Subject)

    8/14/25 4:17:07 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    SEC Form SCHEDULE 13G filed by Omada Health Inc.

    SCHEDULE 13G - Omada Health, Inc. (0001611115) (Subject)

    8/14/25 4:15:16 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    SEC Form 10-Q filed by Omada Health Inc.

    10-Q - Omada Health, Inc. (0001611115) (Filer)

    8/8/25 4:16:56 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    $OMDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hilleman Jeryl L was granted 376 shares, increasing direct ownership by 4% to 10,112 units (SEC Form 4)

    4 - Omada Health, Inc. (0001611115) (Issuer)

    7/8/25 5:18:11 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Director Root Jonathan D was granted 237 shares, increasing direct ownership by 2% to 9,973 units (SEC Form 4)

    4 - Omada Health, Inc. (0001611115) (Issuer)

    7/8/25 4:15:30 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Director Fetter Trevor was granted 257 shares, increasing direct ownership by 3% to 9,993 units (SEC Form 4)

    4 - Omada Health, Inc. (0001611115) (Issuer)

    7/8/25 4:14:24 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    $OMDA
    Financials

    Live finance-specific insights

    View All

    Omada Health to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

    SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2025 results on Thursday, August 7, 2025, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details Those participating in the conference call can pre-register using the following link: https://register-conf.media-server.com/register/BIce129368a015484a8f39659a48a1631e. A live audio webcast of the call will also be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same l

    7/17/25 4:30:00 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care